Gapping up
In reaction to earnings/guidance:
- AMBA +16.6%, BOX +9.8%, GIII +8.3%, ZS +6.9%, PDCO +3.6%, GFS +2.5%, NTAP +2.4%, AIP +1.5%, DOOO +1.2%, RY +1%
Select index ETFs showing strength:
- IWM +2.2%, SPY +1.4%, QQQ +1.4%, DIA +1%
Other news:
- VBIV +15.1% (FDA approval for PreHevbrio)
- BBW +6.6% (declares special dividend of $1.25/sh; authorizes $25 mln share repurchase program)
- GAN +6.5% (approves $5 mln share repurchase authorization)
- VRTX +5.9% (positive results from Phase 2 study of VX-147)
- LI +5.2% (Nov deliveries)
- BHG +5.1% (expects NeueHealth unbit to generate $2 bln in revs in 2022 with meaningful contribution from external payor relationships)
- CNK +4.3% (strong advance sales for Spider-man: No Way Home)
- NTES +4% (provides Cloud Village spin-off and listing update)
- CVE +3.5% (to sell Husky retail fuels network and Wembley assets for nearly $660 mln)
- KXIN +3.5% (provides strategic plan for new energy vehicles)
- XPEV +3.4% (Nov deliveries)
- NIO +3.4% (Nov deliveries)
- AMC +2.8% (strong advance sales for Spider-man: No Way Home)
- SAGE +2.8% (Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD)
- ASX +2.2% (announces the proposed sale and disposal of equity interests in its subsidiaries, GAPT Holding and ASE (Kun Shan) to Wise Road Capital for a cash consideration of $1.46 bln)
- MRK +2.1% (FDA advisory panel narrowly endorses oral pill, according to CNBC; FDA accepts for priority review the supplemental biologics license application for Merck's Vaxneuvance or use in infants and children)
- BITF +2% (Mined over 3,000 Bitcoin in 2021 through November)
- XOM +2% (announces corporate plans to 2027 - supports approximately doubling earnings and cash flow potential)
- VTRS +1.9% (wins Federal Circuit Court appeal upholding District Court decision invalidating Biogen's (BIIB) Tecfidera patent)
- FTFT +1.9% (signed a Strategic Cooperative Letter of Intent with Faya Digital Technology Co., Ltd. to establish a metaverse research and operations platform)
- MA +1.6% (authorizes $8 bln share repurchase program and increases dividend)
- SABS +1.6% (SAB-176 met its primary endpoint in phase 2a challenge study in adults infected with influenza virus)
- RTX +1.5% (awarded $450 mln Navy contract)
Analyst comments:
- ARDX +23.7% (upgraded to Buy from Neutral at Ladenburg Thalmann; tgt $6)
- DASH +3.2% (upgraded to Buy from Hold at Gordon Haskett)
- COF +2.8% (upgraded to Neutral from Underperform at Robert W. Baird)
- AEL +1.1% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
